Compare CYRX & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | SIGA |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.7M | 421.8M |
| IPO Year | N/A | 1997 |
| Metric | CYRX | SIGA |
|---|---|---|
| Price | $9.40 | $6.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $12.83 | N/A |
| AVG Volume (30 Days) | ★ 590.7K | 374.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.27 | 1.03 |
| Revenue | ★ $243,795,000.00 | $172,249,641.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.26 | $132.36 |
| P/E Ratio | $7.44 | ★ $6.27 |
| Revenue Growth | ★ 41.27 | N/A |
| 52 Week Low | $4.58 | $4.95 |
| 52 Week High | $11.44 | $9.62 |
| Indicator | CYRX | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 48.09 |
| Support Level | $9.08 | $6.13 |
| Resistance Level | $10.30 | $6.55 |
| Average True Range (ATR) | 0.46 | 0.21 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 42.94 | 86.81 |
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.